Claudio Bravo Carillo, MD

HS Assoc Clinical Professor

Dr. Claudio Bravo, MSc, FACC, FESC, FAHA, is a physician-scientist and currently an Associate Professor of Medicine and a heart failure and transplant cardiologist at UCSF. He completed fellowship training in Advanced Heart Failure and Transplant Cardiology at Columbia University and holds a Master of Science in Epidemiology from the University of Washington. His primary contributions include describing the role of adenylyl cyclase type 5 blockade in animal models of heart failure and studying outcomes of patients with advanced heart failure using continuous flow LVADs. His research focuses on discovering new molecular mechanisms and pharmacological targets for treating right ventricular failure using multi-omics. Clinically, Dr. Bravo's goal is to provide top-notch medical care to his patients and to advance the field.

Education
MSc, 2023 - Master of Science - Epidemiology, University of Washington
2020 - Advanced Heart Failure and Transplant, New York Presbyterian Hospital-Columbia University
2019 - Cardiology, Montefiore Medical Center-Albert Einstein School of Medicine
2016 - Internal Medicine, Bridgeport Hospital-Yale University
2013 - Post-doctoral Fellowship, Rutgers University
MD, 2008 - Medicine, Universidad Católica de la Santísima Concepción
Publications

  2. Karatasakis A, Silvestri EG, Nair GG, Zuniga B, Li S, Mahr C, Cheng RK, Stempien-Otero AS, Dimarakis I, Khorsandi M, Pal JD, Kizer JR, Simon MA, Bravo CA. Heart transplantation outcomes with donation after circulatory death in patients with left ventricular assist device. ESC heart failure 2025. PMID: 40574369


  3. Bravo CA, Chassagne F, Aliseda A, Beckman JA, Li S, Mahr C. Percutaneous Assessment and Intervention of Outflow Graft Stenosis in Left Ventricular Assist Device Patients-A Cohort Study. ASAIO journal (American Society for Artificial Internal Organs : 1992) 2025. PMID: 40178531


  4. Pi H, Xia L, Boucherat O, Suresh K, Hemnes AR, Bonnet S, Bravo CA, Oppegard L, Rayner SG, Shojaie A, Gharib SA, Leary PJ. Proteomic Signatures of Right Ventricular Outcomes in Pulmonary Arterial Hypertension. Circulation. Heart failure 2024. PMID: 39435559


  5. Braghieri L, Olivas-Martinez A, Silvestri EG, Karatasakis A, Li S, Mahr C, Bravo C. The Impact of the 2018 Allocation System Change on Patients Bridged With Durable Left Ventricular Assist Device: An Updated UNOS Registry Analysis. ASAIO journal (American Society for Artificial Internal Organs : 1992) 2024. PMID: 38207111


  6. Dimarakis I, Callan P, Khorsandi M, Pal JD, Bravo CA, Mahr C, Keenan JE. Pathophysiology and management of valvular disease in patients with destination left ventricular assist devices. Frontiers in cardiovascular medicine 2022. PMID: 36407458


  7. Bahl A, Qureshi B, Zhang K, Bravo C, Mahr C, Li S. Explainable Machine Learning Analysis of Right Heart Failure After Left Ventricular Assist Device Implantation. ASAIO journal (American Society for Artificial Internal Organs : 1992) 2022. PMID: 36730914


  8. Bravo CA, Navarro AG, Dhaliwal KK, Khorsandi M, Keenan JE, Mudigonda P, O'Brien KD, Mahr C. Right heart failure after left ventricular assist device: From mechanisms to treatments. Frontiers in cardiovascular medicine 2022. PMID: 36337897


  9. Berardi C, Bravo CA, Li S, Khorsandi M, Keenan JE, Auld J, Rockom S, Beckman JA, Mahr C. The History of Durable Left Ventricular Assist Devices and Comparison of Outcomes: HeartWare, HeartMate II, HeartMate 3, and the Future of Mechanical Circulatory Support. Journal of clinical medicine 2022. PMID: 35407630


  10. Hameed I, Hameed NUF, Oakley CT, Gambardella I, Bravo C, Angiolillo DJ, Gaudino M. Systematic Assessment of Online Health Information for Coronary Revascularization. JAMA internal medicine 2021. PMID: 33871563


  11. Bravo CA, Fried JA, Willey JZ, Javaid A, Mondellini GM, Braghieri L, Lumish H, Topkara VK, Kaku Y, Witer L, Takayama H, Takeda K, Sayer G, Uriel N, Demmer RT, Naka Y, Yuzefpolskaya M, Colombo PC. Presence of Intracardiac Thrombus at the Time of Left Ventricular Assist Device Implantation Is Associated With an Increased Risk of Stroke and Death. Journal of cardiac failure 2021. PMID: 34161806


  12. Yamada T, Ueyama H, Chopra N, Yamaji T, Azushima K, Kobayashi R, Kinguchi S, Urate S, Suzuki T, Abe E, Saigusa Y, Wakui H, Partridge P, Burger A, Bravo CA, Rodriguez MA, Ivey-Miranda J, Tamura K, Testani J, Coca S. Systematic Review of the Association Between Worsening Renal Function and Mortality in Patients With Acute Decompensated Heart Failure. Kidney international reports 2020. PMID: 32954072


  13. Bravo CA, Hua S, Deik A, Lazar J, Hanna DB, Scott J, Chai JC, Kaplan RC, Anastos K, Robles OA, Clish CB, Kizer JR, Qi Q. Metabolomic Profiling of Left Ventricular Diastolic Dysfunction in Women With or at Risk for HIV Infection: The Women's Interagency HIV Study. Journal of the American Heart Association 2020. PMID: 32063116


  14. Olmedo W, Villablanca PA, Sanina C, Walker J, Weinreich M, Brevik J, Avendano R, Bravo CA, Romero J, Ramakrishna H, Babaev A, Attubato M, Hernandez-Suarez DF, Cox-Alomar P, Pyo R, Krishnan P, Wiley J. Bivalirudin versus heparin in patients undergoing percutaneous peripheral interventions: A systematic review and meta-analysis. Vascular 2018. PMID: 30501582


  15. Rios SA, Bravo CA, Weinreich M, Olmedo W, Villablanca P, Villela MA, Ramakrishna H, Hirji S, Robles OA, Mahato P, Gluud C, Bhatt DL, Jorde UP. Meta-Analysis and Trial Sequential Analysis Comparing Percutaneous Ventricular Assist Devices Versus Intra-Aortic Balloon Pump During High-Risk Percutaneous Coronary Intervention or Cardiogenic Shock. The American journal of cardiology 2018. PMID: 30146099


  16. Zhang J, Levy D, Oydanich M, Bravo CA, Yoon S, Vatner DE, Vatner SF. A novel adenylyl cyclase type 5 inhibitor that reduces myocardial infarct size even when administered after coronary artery reperfusion. Journal of molecular and cellular cardiology 2018. PMID: 29800555


  17. Bravo CA, Hirji SA, Bhatt DL, Gluud C, Faxon DP, Ohman EM, Kaneko T, Engstrøm T, Høfsten DE, Brennan JM. Cochrane corner: complete versus culprit-only revascularisation in ST segment elevation myocardial infarction with multivessel disease. Heart (British Cardiac Society) 2018. PMID: 29439169


  18. Stawiarski K, Kataria R, Bravo CA, Villablanca P, Mohananey D, Narasimhan S, Ramakrishna H. Dual-antiplatelet Therapy Guidelines and Implications for Perioperative Management. Journal of cardiothoracic and vascular anesthesia 2017. PMID: 29398381


  19. Bravo CA, Hirji SA, Bhatt DL, Kataria R, Faxon DP, Ohman EM, Anderson KL, Sidi AI, Sketch MH, Zarich SW, Osho AA, Gluud C, Kelbæk H, Engstrøm T, Høfsten DE, Brennan JM. Complete versus culprit-only revascularisation in ST elevation myocardial infarction with multi-vessel disease. The Cochrane database of systematic reviews 2017. PMID: 28470696


  20. Bravo CA, Vatner DE, Vatner SF. Response to Letter to the Editor on "Does Vidarabine Mediate Cardioprotection via Inhibition of AC5?". The Journal of pharmacology and experimental therapeutics 2016. PMID: 27402380


  21. Bravo CA, Vatner DE, Pachon R, Zhang J, Vatner SF. A Food and Drug Administration-Approved Antiviral Agent that Inhibits Adenylyl Cyclase Type 5 Protects the Ischemic Heart Even When Administered after Reperfusion. The Journal of pharmacology and experimental therapeutics 2016. PMID: 26941173


  22. Lai L, Yan L, Gao S, Hu CL, Ge H, Davidow A, Park M, Bravo C, Iwatsubo K, Ishikawa Y, Auwerx J, Sinclair DA, Vatner SF, Vatner DE. Type 5 adenylyl cyclase increases oxidative stress by transcriptional regulation of manganese superoxide dismutase via the SIRT1/FoxO3a pathway. Circulation 2013. PMID: 23536361


  23. Bravo C, Kudej RK, Yuan C, Yoon S, Ge H, Park JY, Tian B, Stanley WC, Vatner SF, Vatner DE, Yan L. Metabolomic analysis of two different models of delayed preconditioning. Journal of molecular and cellular cardiology 2012. PMID: 23127662


  24. Iwatsubo K, Bravo C, Uechi M, Baljinnyam E, Nakamura T, Umemura M, Lai L, Gao S, Yan L, Zhao X, Park M, Qiu H, Okumura S, Iwatsubo M, Vatner DE, Vatner SF, Ishikawa Y. Prevention of heart failure in mice by an antiviral agent that inhibits type 5 cardiac adenylyl cyclase. American journal of physiology. Heart and circulatory physiology 2012. PMID: 22505646